Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has changed significantly since the development of oral Bruton’s tyrosine kinase (BTK) inhibitors. While chemoimmunotherapy was previously the standard of care for first-line treatment, BTK inhibitors have p...

Descripción completa

Detalles Bibliográficos
Autores principales: St-Pierre, Frédérique, Ma, Shuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325877/
https://www.ncbi.nlm.nih.gov/pubmed/35911566
http://dx.doi.org/10.2147/BLCTT.S326627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325877/
https://www.ncbi.nlm.nih.gov/pubmed/35911566
http://dx.doi.org/10.2147/BLCTT.S326627

Ejemplares similares